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Impact of a 2‑year trial of nutritional ketosis
on indices of cardiovascular disease risk
in patients with type 2 diabetes
Shaminie J. Athinarayanan1† , Sarah J. Hallberg1,2,3†, Amy L. McKenzie1, Katharina Lechner4,5, Sarah King6,
James P. McCarter7,8, Jeff S. Volek1,9, Stephen D. Phinney1 and Ronald M. Krauss6*

Abstract
Background: We have previously reported that in patients with type 2 diabetes (T2D) consumption of a very low
carbohydrate diet capable of inducing nutritional ketosis over 2 years (continuous care intervention, CCI) resulted in
improved body weight, glycemic control, and multiple risk factors for cardiovascular disease (CVD) with the exception of an increase in low density lipoprotein cholesterol (LDL-C). In the present study, we report the impact of this
intervention on markers of risk for atherosclerotic cardiovascular disease (CVD), with a focus on lipoprotein subfraction
particle concentrations as well as carotid-artery intima-media thickness (CIMT).
Methods: Analyses were performed in patients with T2D who completed 2 years of this study (CCI; n = 194; usual
care (UC): n = 68). Lipoprotein subfraction particle concentrations were measured by ion mobility at baseline, 1,
and 2 years and CIMT was measured at baseline and 2 years. Principal component analysis (PCA) was used to assess
changes in independent clusters of lipoprotein particles.
Results: At 2 years, CCI resulted in a 23% decrease of small LDL IIIb and a 29% increase of large LDL I with no change
in total LDL particle concentration or ApoB. The change in proportion of smaller and larger LDL was reflected by
reversal of the small LDL subclass phenotype B in a high proportion of CCI participants (48.1%) and a shift in the
principal component (PC) representing the atherogenic lipoprotein phenotype characteristic of T2D from a major to
a secondary component of the total variance. The increase in LDL-C in the CCI group was mainly attributed to larger
cholesterol-enriched LDL particles. CIMT showed no change in either the CCI or UC group.
Conclusion: Consumption of a very low carbohydrate diet with nutritional ketosis for 2 years in patients with type 2
diabetes lowered levels of small LDL particles that are commonly increased in diabetic dyslipidemia and are a marker
for heightened CVD risk. A corresponding increase in concentrations of larger LDL particles was responsible for higher
levels of plasma LDL-C. The lack of increase in total LDL particles, ApoB, and in progression of CIMT, provide supporting evidence that this dietary intervention did not adversely affect risk of CVD.
Keywords: Type 2 diabetes, Nutritional ketosis, Cardiovascular risk, Lipoprotein sub-fractionation, Atherogenic
lipoprotein phenotype
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Background
Global incidence of diabetes is rising substantially, with
the expectation of a 50% increase between 2015 and 2040
[1]. The leading cause of death in patients with diabetes
is cardiovascular disease (CVD) [2] and mitigating CVD
risk has become a principal focus of current diabetes
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guidelines [3, 4]. Multiple studies have found that therapeutic carbohydrate restriction significantly improves a
number of CVD risk factors [5–7], including elevated triglycerides and small dense LDL, low HDL-C, and markers of non-alcoholic fatty liver disease [8, 9]. These factors
contribute to residual risk of CVD following statin treatment for lowering of LDL-cholesterol (LDL-C) [10].
Although LDL-C has been a mainstay for CVD risk
prediction and management for decades, it is not characteristically elevated in patients with diabetes. Rather,
the most common dyslipidemia in type 2 diabetes (T2D)
consists of high triglycerides (TG), low HDL-cholesterol
(HDL-C), and a preponderance of small dense LDL particles [11, 12]. This trait which is a central feature of metabolic syndrome, has been designated the atherogenic
lipoprotein phenotype (ALP) or atherogenic dyslipidemia
[11–14]. Multiple studies have shown beneficial effects
of carbohydrate restriction on this phenotype [15–17].
Recently, very low carbohydrate diets that achieve nutritional ketosis have been shown to be of benefit in diabetes management, with effects including improvements in
weight, HbA1c, triglycerides and HDL-C [5, 18]. However, such diets often result in increased concentrations
of LDL-C [18, 19], which has raised concerns regarding
an adverse effect on CVD risk.
While LDL-C is taken to reflect the role of LDL particles in the development of CVD, it has been shown that
measurement of LDL particles [20, 21] and ApoB, which
is a measure of the number of all atherogenic particles
(LDL, IDL, VLDL, lipoprotein (a), chylomicron remnants) [20, 22] can provide superior assessment of CVD
risk, most notably when there is discordance between
LDL-C and LDL particle concentrations [22]. This discrepancy is commonly due to increased levels of small,
dense, cholesterol-depleted particles, as is the case for
the dyslipidemia of T2D. There is increasing evidence
that levels of small, dense LDL are predictive of CVD
incidence independent of LDL-C [23–27], whereas in
general levels of large LDL show weak or absent associations with CVD risk [27]. Properties of small LDL that
may underlie this risk include increased circulation time
due to decreased receptor-mediated uptake, increased
vascular wall binding, and increased susceptibility to oxidation and glycation [28]. Assessment of other lipoprotein particle subclasses, including those within VLDL and
HDL, has provided the ability to further assess CVD risk
[20].
We previously reported that 2 years of treatment with a
continuous care intervention (CCI) produced significant
improvements in weight, blood glucose, HbA1c, liver
function, and inflammatory markers with no adverse
effects on kidney markers [29]. Participants in the CCI
group had a 0.9% mean absolute reduction in HbA1c and
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a 10% average weight loss at 2 years [29]. CCI is a personalized carbohydrate restriction (CR) intervention with
guidance encouraging nutritional ketosis that is delivered
and supported remotely using a telemedicine-approach,
via one-to-one health coaching and physician-led treatment. At 1 year, the intervention resulted in substantial
improvements in multiple cardiometabolic risk markers
including triglycerides, HDL-C, ApoA1, ApoB: ApoA1
ratio, and blood pressure [30, 31]. However, there was an
increase in LDL-C that was maintained through 2 years
despite sustained improvements in TG and HDL-C
[30]. To further characterize changes in LDL and other
lipoproteins at 1 and 2 years, we have here utilized the
technique of ion mobility (IM) which directly measures
concentrations of lipoprotein particle subclasses across
the full diameter spectrum from HDL to VLDL. The
primary aims were to investigate the effect of the CCI
and UC on lipoprotein subfractions and carotid intimamedia thickness (CIMT). Secondary aims included:
(1) investigating the effect of CCI and UC on T2D atherogenic dyslipidemia using both principal component
analyses and assessment of LDL subclass phenotypes and
(2) among the CCI participants, comparing the 2-year
changes of lipoprotein subclasses and CIMT between
individuals in the highest and lowest quartiles of either
LDL-C or ApoB responses. Other ancillary aims included
assessing potential relationships between adiposity and
beta-hydroxybutyrate (BHB) with changes in lipids, lipoproteins and LDL phenotype.

Materials and methods
Study design and intervention

The data analyzed for this study are measurements of
CVD risk markers obtained at baseline and after 1 and
2 years of follow-up in participants in the clinical trial
NCT02519309. This is an open-label, non-randomized
controlled trial of the effects of carbohydrate restriction including nutritional ketosis conducted in a cohort
of patients with T2D. The study design, comprehensive
details of the study intervention, and major exclusion
criteria were previously published [29, 31]. Briefly, the
trial recruited participants with an established diagnosis of T2D and a body mass index (BMI) > 25 kg/m2, who
self-selected to receive either the CCI or usual care (UC).
All study participants were informed and consented
to participate in the study, and the study was approved
by the Franciscan Health Lafayette Institutional Review
Board. Patients in the CCI group received nutritional
advice on carbohydrate restriction to achieve and sustain nutritional ketosis. They were initially advised to
consume < 30 g of carbohydrates, approximately 1.5 g
protein per kg reference body weight, and fat to satiety
each day. Blood beta-hydroxybutyrate (BHB) was used as
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a marker of carbohydrate restriction, with BHB ≥ 0.5 mM
[32] indicating nutritional ketosis. Over time, BHB and
dietary intake targets were modified according to patient
health needs, goals, and values. The patients had access
to a web-interfaced software application (app) that they
used to communicate with their remote care team and
receive telemedicine-based treatment. The app was used
to upload selected biomarkers for monitoring adherence
to nutritional intervention and health-related progress
including body weight, blood glucose, and BHB. The frequency of reporting glucose and BHB was adjusted to
each participant’s preferences and current health needs.
Participants with a confirmed history of hypertension
additionally received an automatic sphygmomanometer,
blood pressure readings were uploaded in the app for
assessment by the care team. The reported blood glucose
and blood pressure readings were evaluated routinely by
the physician who adjusted diabetic and anti-hypertensive prescriptions as needed. Via the app, participants
had access to online resources and the opportunity to
participate in an online social support community.
Patients who chose UC comprised a reference group
that was recruited from the same geographical and
healthcare system. They continued with their existing
care team without modification and received nutritional
and lifestyle advice as recommended by the American
Diabetes Association (ADA) between August 2015 and
May 2018 [3]. No study-specific modification of treatment or care was made but the participants in the UC
arm were required to obtain annual tests for measurement of clinical biomarkers.
Anthropometric measures

Anthropometric measures were obtained for both CCI
and UC participants in the clinic at baseline, 1 year, and
2 years. Body weight and height were measured using a
stadiometer and calibrated scale, respectively and the values were used to calculate body mass index (BMI). Manual blood pressure measurements were performed by
trained staff. Dual-energy X-ray absorptiometry (DXA;
Lunar GE Prodigy, Madison, WI) was utilized to measure
total body composition and to estimate central abdominal fat (CAF), as previously described [29], in the CCI
group only.
Lipid analyses

An accredited Clinical Laboratory Improvement Amendment (CLIA) laboratory was used to analyze all the
standard blood analytes. For the determination of total
cholesterol, HDL-C, TG, ApoA1, and ApoB, an enzymatic, colorimetric method was employed using FDA
approved Cobas c501 (Roche Diagnostics; Indianapolis,
IN, USA) assays. LDL cholesterol (LDL-C) levels were
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calculated using the Friedewald equation, except if the
TG level exceeded 400 mg/dL, in which case LDL-C was
not determined (n = 15, 8, 8 in CCI and n = 9, 10, 6 in
UC at baseline, 1 year and 2 years, respectively). ApoB:
ApoA1 ratios were computed. Non-HDL cholesterol
was calculated as total minus HDL cholesterol and remnant cholesterol was assessed as total cholesterol minus
(HDL-cholesterol plus LDL-cholesterol).
Lipoprotein analyses

Particle concentrations of VLDL, IDL, LDL, and HDL
subfractions were analyzed in specific particle-size intervals using ion mobility (IM), which uniquely allows for
direct particle quantification as a function of particle
diameter [21] following a procedure to remove other
plasma proteins [24]. The IM instrument utilizes an
electrospray to create an aerosol of particles which then
pass through a differential mobility analyzer coupled
to a particle counter. Particle concentrations (nmol/L)
were measured in 11 size intervals (Å): VLDL: large
(424.0 to 547.0), medium (335.0 to 424.0), small (296.0
to 335.0); IDL: large (250.0 to 296.0) and small (233.3 to
250.0); LDL: large LDL I (224.6 to 233.3), medium LDL
IIa (220.0 to 224.6), and LDL IIb (214.1 to 220.0), small
LDL IIIa (208.2 to 214.1) and LDL IIIb (204.9 to 208.2),
very small LDL IVa (199.0 to 204.9), LDL IVb (190.0 to
199.0) and LDL IVc (180.0 to 190.0); HDL: large HDL 2b
(105.0 to 145.0) and smaller HDL 2a + 3 (76.5 to 105.0).
In addition, particles in the size range between LDL and
HDL (145.0 to 180.0 Å) were measured (designated midzone). Peak LDL diameter was determined as described
[22]. Interassay variation was reduced by the inclusion of
two in-house controls in each preparatory process and
triplicate analysis. Inter- and intra-assay coefficients of
variability were < 15% for lipoprotein subclass concentrations and < 0.8% for LDL peak diameter. In addition, LDL
subclass phenotypes were determined as described previously [33]: phenotype A (predominance of larger LDL
particles with LDL peak diameter > 21.88 nm), phenotype
B (predominance of small LDL particles with LDL peak
diameter < 21.55 nm), or intermediate phenotype I (with
LDL peak diameter between 21.55 and 21.88 nm).
Carotid intima‑media thickness (CIMT) measurement

Ultrasound assessment CIMT was performed in both
CCI and UC participants. A high-resolution B mode
carotid ultrasound was used (Philips EPIQ5 system;
Amsterdam, Netherlands) and the scans were performed
by trained and blinded technicians. The participants
were placed in a supine position, and both right and left
carotid arteries were evaluated with grayscale, spectral,
and color Doppler images. The images were taken 1 cm
distal to the carotid bulb, below its bifurcation limit. As
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previously published [30], three imaging planes, anterior,
lateral, and posterior, were captured for each participant.
These images were then analyzed using the edge detection software (Carotid Analyzer for Research, Medical
Imaging Application, Coralville, IA) by a trained and
blinded analyst. Any images that were classified “poor”
and those with missing planes were removed from all the
time points, before the right and left mean CIMT and
diameter were calculated from the images. The right and
left CIMT average measurements were then used to calculate the overall mean CIMT.
Statistical analyses

Analyses were performed using IBM SPSS Statistics for
Windows, version 26.0 (IBM Corp, Armonk, N.Y., USA).
All were first examined for normality and linearity using
the skewness and kurtosis cut-offs suggested by Kline’s
2011 guidelines [34]. Four outcomes were positively
skewed (i.e., triglycerides, LDL IVa, LDL IVb, and LDL
IVc), these variables were normalized by either removal
of the top 1% of values or natural log transformations (as
specified in the tables’ footnotes). Between-group and
between completers versus dropouts’ differences in baseline data were analyzed using independent sample t-tests.
All analyses were based on the per-protocol principle
including only participants with available data at baseline and 2 years. We used linear mixed-effects models (LMMs) to analyze all the primary endpoints. The
models included fixed effects of time, treatment group,
and time-by-group interaction to estimate the adjusted
means at each time point and to assess the time-effect
of the treatments (baseline to 2 years) and betweentreatment group differences (CCI versus UC). All models were adjusted for baseline age, sex, BMI, insulin use,
statin use, HDL 2 + 3a, and mid-zone. BMI, insulin-use,
HDL 2 + 3a and mid-zone were included as co-variates
because they differed significantly between CCI and UC
groups at baseline. A sensitivity analysis was conducted
using data including all participants (262 CCI and 87 UC
participants) based on the intent-to-treat principle. The
estimation of the missing data in the LMMs was based
on the maximum likelihood approach and an unstructured (UN) covariance structure was used to account
for within-group correlation over time. The changes in
the proportion of participants’ use of lipid-lowering and
antihypertensive medications between baseline versus
2 years in both CCI and UC were analyzed using McNemar’s test with continuity correction when appropriate.
Logistic generalized estimating equations (GEE) analysis with an unstructured covariance matrix were used to
analyze the time-effect of each treatment group (CCI and
UC) on the trichotomous categorical variable, LDL phenotype pattern (Pattern A, B and I). Covariates included
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baseline age, sex, BMI, insulin use, statin use, HDL 2 + 3a,
and mid-zone.
Individual differences in the changes of LDL-C and
ApoB between baseline and 2 years were assessed using
hypo- and hyper-responder categories. For the classification of LDL-C and ApoB hypo- versus hyper-responders,
we generated quartiles using the calculated delta LDL-C
and delta ApoB from baseline to 2 years. The lowest
(greatest decrease) and highest (greatest increase) quartiles were classified as hypo- and hyper-responders,
respectively. A-one-way MANOVA was performed to
assess the differences in the multivariate lipoprotein
profiles at 2 years for the LDL-C and ApoB hypo- versus
hyper-responders. Lipoprotein variables that failed the
Shapiro–Wilk test of normality were log-transformed
before inclusion in the MANOVA to meet the multivariate normality and outliers’ assumptions. The 2-year differences in mean CIMT between the LDL-C or ApoB
hypo- and hyper-responder groups were assessed using
independent T-tests.
Finally, measures of adiposity and BHB were tested
as predictors of changes in lipids and lipoproteins. Linear and multiple linear regression analyses were used
to assess the relationships between changes in BMI
and CAF with lipids and lipoproteins. BHB values that
were uploaded in the app by the CCI participants were
treated as count data, where the number of days participants reported a BHB value of ≥ 0.5 mM over the past
24 months was modeled using negative binomial regression for association with lipids, lipoproteins, and LDL
phenotype shift.
A strict Bonferroni correction was applied to the LMM
and MANOVA analyses, where P < 0.0015 and P < 0.003,
respectively indicated statistical significance. For all other
exploratory analyses, P < 0.05 was used to determine statistical significance.
Principal component analysis

There was a strong inter-correlation and dependency
between the lipoprotein subclasses and lipid variables.
To simplify analysis, principal component analysis (PCA)
was performed on the 16 lipoproteins and 3 traditional
lipids to reduce the variables by generating a new independent combination of the variables that explains the
variance of the data. Separate PCAs were performed on
baseline and 2-year follow-up data in the CCI and UC
treatment groups. Three steps were used: (1) Identification and extraction of major principal components, (2)
Rotation of the principal components to identify relevant loading factors, and (3) Interpretation of the principal components and its associated variance. First, we
assessed the data for sampling adequacy and its suitability for factor analysis using the Kaiser–Meyer–Olkin
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(KMO) statistic (cut-off > 0.6) and the Barlett test of sphericity (P < 0.001). Then, we performed PCA on the baseline CCI (n = 223) and UC (n = 70), and 2-year follow-up
CCI (n = 140) and UC (n = 46) data, separately. The major
principal components represented in each dataset were
extracted after assessing the scree plots, and an eigenvalue of 1 was used as a cut-off to select and retain the
principal components. We used both varimax and promax rotation methods to identify loading factors for each
principal component and a loading value cut-off > 0.40
was used to determine the individual lipoproteins and
lipids represented in each component. The individual
extracted principal components and their associated variance at baseline and 2-years follow-up were qualitatively
assessed. The variance of the individual PCs at baseline
and 2-years explains how much of the information in the
data is captured by the respective PCs. A PC with the
highest variance contribution represents the most information in the data, while a PC with less variance captures
less information in the data. Changes in the rank of the
PCs were assessed at baseline and 2 years.

Results
Participant characteristics

This study enrolled 262 CCI and 87 UC participants,
with 194 CCI and 68 UC participants remaining enrolled
for 2 years. As previously reported [20], baseline demographic characteristics of the two treatment groups were
similar except for the proportion of African Americans.
Baseline anthropometric measures, CVD risk markers,
and average CIMT were similar between CCI and UC,
except for BMI (Additional file 1: Table S1). Baseline levels of lipoprotein subclasses were similar between CCI
and UC groups, except for mid-zone and small HDL
2a + 3 which were significantly lower in the CCI group.
At baseline, 50% of CCI and 59% of UC participants were
on statin treatment (P = 0.16). There were no significant differences in baseline characteristics of those who
dropped out of the study versus those remaining, except
for the baseline proportion of LDL phenotypes in UC
(Additional file 1: Table S1).
Changes in primary laboratory and clinical outcome
measures

Within the UC group, no changes over time in lipids,
lipoproteins, apoproteins, blood pressure, CIMT and
lipid-lowering and anti-hypertensive medications were
observed. Among CCI participants at 1 and 2 years,
mean LDL-C and HDL-C increased, mean TG and blood
pressure decreased, and total cholesterol was unchanged,
as previously reported [20] (Additional file 1: Table S2,
Figure S1). Lower blood pressures were observed concurrent with reduced use of antihypertensive medication
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(P = 1.0 × 10–3), particularly diuretics (P = 7.0 × 10–3)
at 2 years (Additional file 1: Table S3). The use of statin medication was unchanged at 2 years, but the use of
other lipid-lowering medications (bile acid sequestrants,
fibrates, niacin and omega-3 fatty acid ethyl esters)
decreased (P = 8.0 × 10–3) from a small baseline population of 9.3%.
Among CCI participants, remnant cholesterol
decreased at 1 and 2 years (− 22.4% at 2 years,
P = 3.1 × 10–7), and ApoA1 increased (+ 10.9% at 2 years,
P = 1.4 × 10–7; Additional file 1: Table S2). Non-HDL,
ApoB, ApoB: ApoA1 ratio, and CIMT were unchanged
(Additional file 1: Table S2). No significant changes in
total LDL, total IDL, total VLDL, and total HDL particles were seen in the CCI and UC groups. Among lipoprotein subfractions, VLDL subclasses and IDL I were
unchanged at 2 years, while IDL II increased (+ 24.6%
at 2 years, P = 2.0 × 10–10, Table 1, Additional file 1: Figure S1) and was greater than UC (P = 5.1 × 10–8). Large
LDL I increased at one and 2 years (+ 29.1% at 2 years,
P = 2.4 × 10–8) concurrent with increases in LDL peak
diameter (+ 2.0% at 2 years, P = 1.9 × 10–10); both were
greater compared to UC (P = 2.0 × 10–6 and P = 1.2 × 10–
4
, respectively). LDL IIa and IIb were unchanged. Small
LDL IIIa and IIIb decreased at 1 year, with LDL IIIb
maintaining significance at 2 years (− 23.1% at 2 years,
P = 1.0 × 10–3) where it was lower compared to UC
(P = 1.0 × 10–3) (Table 1), while the reduction in LDL IIIa
at 2 years was of borderline significance after Bonferroni
correction (P = 3.0 × 10–3). There were non-significant
decreases in very small LDL (IVa–c). Particles in the
mid-zone were lower at 1 and 2 years (− 6.8% at 2 years,
P = 7.4 × 10–7) and compared to UC (P = 1.0 × 10–3).
No significant differences in HDL subfractions were
observed in either CCI or UC groups. An intent-to-treat
sensitivity analysis using all available data revealed results
consistent with the per-protocol (completers) analysis
(Additional file 1: Table S4).
Changes in principal components and LDL subclass
phenotypes

Principal component analysis was performed on the
baseline and 2-year data separately in the CCI and UC
groups. At baseline data, for the CCI group, three major
principal components (PC1, PC2, PC3) were extracted
accounting for 39.9%, 24.8%, and 12.7% of the total variance (77.4%), respectively. PC1 consisted of contributions from small LDLs (LDL IIIa to LDL IVc), large
VLDL, medium VLDL, and TG in the positive direction
and HDL-C in the negative direction (Additional file 1:
Table S5). Major contributors of PC2 were large and
medium LDLs (LDL I to LDL IIb), IDLs, VLDL small,
and LDL-C in a positive direction. Finally, contributors of
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Table 1 Adjusted means and changes in lipoproteins over time by treatment group among completers
Variables

Visit

Continuous care intervention (n = 194) Usual care (n = 68)
Mean ± SE

Total VLDL (nmol/L)

Baseline
1 year
2 years

VLDL large (nmol/L)

Baseline
1 year
2 years

VLDL medium
(nmol/L)

Baseline
1 year
2 years

VLDL small (nmol/L)

Baseline
1 year
2 years

Total IDL (nmol/L)

Baseline
1 year
2 years

IDL 1 (nmol/L)

Baseline
1 year
2 years

IDL 2 (nmol/L)

Baseline
1 year
2 years

Total LDL (nmol/L)

Baseline
1 year
2 years

LDL I (nmol/L)

Baseline
1 year
2 years

LDL IIa (nmol/L)

Baseline
1 year
2 years

LDL IIb (nmol/L)

Baseline
1 year
2 years

LDL IIIa (nmol/L)

Baseline
1 year
2 years

LDL IIIb (nmol/L)

Baseline
1 year
2 years

LDL IVa (nmol/L)a

Baseline
1 year
2 years

LDL IVb (nmol/L)a

Baseline
1 year
2 years

138.6 ± 5.7

128.7 ± 5.8

129.3 ± 5.9
23.9 ± 1.0

19.1 ± 1.0

20.3 ± 1.0

57.3 ± 1.8

52.3 ± 1.8

Change from baseline
(Mean, CI)

− 9.9, − 25.8 to 5.9

− 9.3, − 25.3 to 6.6

− 4.8, − 7.6 to − 2.0*

− 3.6, − 6.4 to − 0.8
− 5.0, − 10.0 to 0.0

52.5 ± 1.8

− 4.7, − 9.7 to 0.3

63.2 ± 1.5

3.9, − 0.3 to 8.1

59.3 ± 1.5

59.2 ± 1.5

256.6 ± 8.0

285.1 ± 8.3

288.9 ± 8.4

136.2 ± 3.3

139.4 ± 3.3

− 0.1, − 4.3 to 4.1
28.4, 5.9 to 50.9
32.2, 9.6 to 54.9 Ï
3.2, − 5.9 to 12.3

136.4 ± 3.3

0.2, − 8.9 to 9.2

152.1 ± 3.8

30.0, 19.6 to 40.4*

122.1 ± 3.8

156.3 ± 3.8

34.2, 23.9 to 44.6*

991.8 ± 25.9

962.7 ± 26.8 − 29.1, − 101.9 to 43.7

1002.0 ± 27.0 10.3, − 62.8 to 83.4
163.5 ± 6.0

207.7 ± 6.1

44.2, 27.6 to 60.7*

211.1 ± 6.0

47.6, 31.1 to 64.0*

153.4 ± 4.7

15.6, 2.7 to 28.4

137.8 ± 4.7

156.1 ± 4.7

18.3, 5.5 to 31.1 Ï

169.7 ± 5.6

− 6.3, − 21.6 to 9.0

176.0 ± 5.6

174.9 ± 5.6

191.5 ± 7.3

157.4 ± 7.4

161.1 ± 7.3

87.8 ± 4.4

66.5 ± 4.5

− 1.1, − 16.3 to 14.2
− 34.0, − 54.2 to − 13.9*

− 30.3, − 50.4 to − 10.3Ï
− 21.2, − 33.5 to − 9.0*

Mean ± SE

144.0 ± 8.4

146.9 ± 8.7

144.1 ± 8.7
22.2 ± 1.7

22.7 ± 1.8

21.9 ± 1.7

55.2 ± 3.1

54.6 ± 3.2

Between group effect

Change
Mean
from baseline (Mean, difference
CI)

3.0, − 20.3 to 26.2

0.2, − 23.0 to 23.4
0.5, − 4.3 to 5.2

− 0.3, − 5.0 to 4.4
− 0.5, − 9.1 to 8.0

− 5.3

− 18.2

− 14.8
1.7

− 3.6

− 1.6
2.1

− 2.4

54.7 ± 3.1

− 0.5, − 8.9 to 7.9

− 2.2

55.0 ± 2.7

− 0.8, − 8.0 to 6.3

8.2

55.8 ± 2.6

54.9 ± 2.6

255.1 ± 11.9

− 0.9, − 8.0 to 6.1

256.1 ± 12.3 1.1, − 32.0 to 34.1

3.4

4.3
1.6
28.9

261.5 ± 12.3 6.4, − 26.5 to 39.4

27.3

128.8 ± 5.9

129.2 ± 5.7

7.0

− 0.4, − 15.9 to 15.0

10.6

128.3 ± 5.7

− 0.9, − 16.1 to 14.3

112.0 ± 6.7

− 1.3, − 19.0 to 16.4

40.1*

113.3 ± 6.5

114.0 ± 6.5

1028.7 ± 40.8

0.7, − 16.7 to 18.1

8.0
8.8
42.3*
− 36.9

1026.5 ± 43.1 − 2.2, − 117.2 to 112.8 − 63.8

1022.1 ± 42.3 − 6.6, − 120.2 to 107.0 − 20.0
155.6 ± 10.3

7.9

146.1 ± 10.7 − 9.6, − 37.7 to 18.6

61.7*

− 0.6 to 58.4

− 2.3 to 57.0

− 6.2 to 20.1

− 2.9 to 24.1

− 5.1 to 21.1

− 6.3 to 23.8

24.6 to 55.5*
27.2 to 57.3*

− 132.7 to 58.9

− 164.4 to 36.8

− 119.6 to 79.6

− 16.0 to 31.8
37.1 to 86.2*

26.9Ï

8.4 to 45.4Ï

− 4.1, − 30.0 to 21.9

3.7

170.1 ± 9.5

166.0 ± 9.9

171.4 ± 9.5

169.8 ± 12.6

1.3, − 24.3 to 26.9

187.2 ± 13.0 17.4, − 16.7 to 51.6
193.5 ± 12.6 23.8, − 9.9 to 57.4
84.7 ± 7.6

98.0 ± 7.9

13.3, − 7.5 to 34.1

6.0
3.6
21.7
− 29.8

− 32.4
3.1

− 31.5*

93.1 ± 5.9

− 1.9, − 17.4 to 13.6

− 16.7

− 5.1, − 10.1 to − 0.2

− 1.8 to 10.4

− 27.0 to 30.1

− 6.6, − 28.0 to 14.8

129.2 ± 8.0

− 12.7, − 21.4 to − 4.0Ï

73.2 ± 1.8

− 2.6 to 9.5

2.0 to 14.4

7.8 to 45.9

2.0

76.4 ± 3.2

− 6.7, − 11.7 to − 1.7

− 9.8 to 5.1

− 9.4 to 5.1

26.9

− 29.0*

78.3 ± 1.8

− 5.2 to 9.3

− 9.3, − 31.1 to 12.5

135.8 ± 8.0

11.8, − 8.7 to 32.2

71.6 ± 1.8

− 7.7 to 0.6

− 5.7 to 2.4

126.5 ± 8.3

96.5 ± 7.6

− 12.2, − 20.9 to − 3.6

− 35.7 to 6.0

− 2.3 to 5.7

58.2*

− 20.3, − 32.5 to − 8.1*

76.9 ± 3.2

− 25.4 to 14.8

− 39.0 to 2.5

152.9 ± 10.3 − 2.8, − 30.4 to 24.9

67.5 ± 4.4

89.1 ± 3.2

95% CI

95.0 ± 5.6

− 5.9

89.9 ± 5.6

− 5.1, − 20.2 to 10.1

− 13.1

82.7 ± 3.3

− 0.1, − 8.8 to 8.6

− 11.1Ï

82.8 ± 3.2

81.5 ± 3.2

− 1.3, − 9.9 to 7.5

34.3 to 82.1*
− 16.6 to 20.5

− 16.1 to 28.0

− 19.0 to 26.3

− 18.5 to 25.7

− 7.4 to 50.8

− 59.6 to 0.1

− 61.5 to − 3.3

− 14.6 to 20.7

− 49.6 to − 13.4*

− 46.6 to − 11.3*
− 18.7 to 6.9

− 30.0 to − 3.4

− 25.9 to − 0.2

− 4.5

− 11.8 to 2.8

− 8.3

− 15.6 to − 1.0

− 18.6 to − 3.6Ï
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Table 1 (continued)
Variables

Visit

Continuous care intervention (n = 194) Usual care (n = 68)
Mean ± SE

LDL IVc (nmol/L)a

Baseline
1 year
2 years

Mid-zone (nmol/L)

Baseline
1 year
2 years

Total HDL

Baseline
1 year
2 years

HDL 2b (µmol/L)

Baseline
1 year
2 years

HDL 2a + 3 (µmol/L)

Baseline
1 year
2 years

LDL peak diameters
(Å)

Baseline
1 year
2 years

Change from baseline
(Mean, CI)

88.9 ± 1.3
83.6 ± 1.3

− 5.3, − 8.8 to − 1.7

84.0 ± 1.3

− 5.0, − 8.5 to − 1.4

875.3 ± 8.6

828.6 ± 8.6

815.4 ± 8.6
22.9 ± 0.3

22.8 ± 0.4

22.8 ± 0.4
6.0 ± 0.1

6.3 ± 0.1

6.3 ± 0.1

17.3 ± 0.2

16.8 ± 0.2

17.0 ± 0.2

215.2 ± 0.5

219.6 ± 0.5

219.5 ± 0.5

Ï

− 46.6, − 70.2 to − 23.1*

− 59.9, − 83.4 to − 36.4*
− 0.2, − 1.1 to 0.8

− 0.1, − 1.1 to 0.9
0.4, 0.1 to 0.6Ï
0.3, 0.1 to 0.5

− 0.5, − 0.9 to − 0.0

− 0.3, − 0.8 to 0.1
4.4, 3.1 to 5.7*
4.3, 3.0 to 5.6*

Mean ± SE

Change
Mean
from baseline (Mean, difference
CI)

89.6 ± 2.2
88.6 ± 2.3

− 0.9, − 7.1 to 5.2

85.7 ± 2.2

− 3.8, − 9.8 to 2.2

892.2 ± 14.7

890.5 ± 15.2 − 1.7, − 41.8 to 38.3

876.0 ± 14.7 − 16.2, − 55.6 to 23.2
25.1 ± 0.5

24.8 ± 0.5

25.3 ± 0.5
6.0 ± 0.1

6.0 ± 0.1

6.1 ± 0.1

18.0 ± 0.3

17.5 ± 0.3

17.8 ± 0.3

215.0 ± 0.8

215.1 ± 0.8

215.8 ± 0.8

Between group effect

− 0.3, − 1.7 to 1.1

0.2, − 1.2 to 1.6

− 0.0, − 0.4 to 0.4

0.1, − 0.3 to 0.5

− 0.5, − 1.2 to 0.3

− 0.2, − 0.9 to 0.6
0.1, − 2.1 to 2.3

0.8, − 1.4 to 3.0

95% CI

− 0.6

− 5.8 to 4.5

− 5.0

− 10.3 to 0.3

− 1.8

− 16.9

− 61.8*

− 60.6*
− 2.2

− 2.0

− 2.5
0.0

0.3
− 0.1

− 0.7

− 0.7

− 0.8
0.2

− 6.9 to 3.4

− 50.9 to 17.1

− 96.7 to − 26.9*

− 94.6 to − 26.5*

− 3.4 to − 0.9

− 3.3 to − 0.7

− 3.8 to − 1.2

− 0.3 to 0.2
0.0 to 0.7

− 0.2 to 0.5

− 1.3 to − 0.1

− 1.4 to − 0.0

− 1.5 to − 0.2

− 1.7 to 2.1

4.5*

2.6 to 6.5*

3.7*

1.8 to 5.6*

Adjusted means and mean changes were obtained from an analysis using linear mixed-effects model (LMM) controlling for baseline age, sex, race, body mass index,
HDL 2 + 3a, mid-zone, insulin use and statin use

SE standard error, CI 95% confidence interval, LDL low density lipoprotein, HDL high-density lipoprotein, IDL intermediate density lipoprotein, VLDL very low-density
lipoprotein, CIMT carotid intima-media thickness
a

Variables normalized by removing the top 1% of values. Analyses were conducted excluding the top 1% values, although all cases were included using the
maximum likelihood approach

b

Variables normalized by natural log transformation. Non-transformed and unadjusted means, mean changes, CI and standard errors were provided in the table, but
the significance level is calculated from the transformed analysis

*

P < 0.0015 ensures overall simultaneous significance of P < 0.05 over the 33 variables using Bonferroni correction

Ï

P < 0.005

PC3 were HDL subclasses (HDL 2b and HDL 2a + 3), the
mid-zone fraction and very small LDL IVc in the positive
direction. From the 2-year data in the CCI group, four
principal components were extracted explaining 82.7%
of the overall variance. The major component explained
39.9% of the total variance and was consistent with PC2
of baseline data (Additional file 1: Table S5). The next
two components were both consistent with PC1 of baseline data and were therefore designated PC1a and PC1b,
accounting for 22.9% and 13.9% of the variance, respectively. Small and very small LDLs contributed to both
PC1a and PC1b with a greater contribution from small
LDLs (LDL IIIa and IIIb) in PC1a and very small LDLs
(LDL IVa to LDL IVc) in PC1b. PC1a was also represented by all VLDLs (mainly medium and large) and TG
in a positive and HDL-C in a negative direction. PC1b
was strongly represented by the mid-zone fraction and

was also moderately associated with TG, and medium
and large VLDLs. The last extracted component
explained 6.1% of the variance and corresponded closely
to PC3 of the baseline data (Additional file 1: Table S5).
PCA on both baseline and follow-up UC data consistently extracted three components which corresponded
closely to the PCs extracted from the baseline CCI data,
except that HDL-C was not loaded in PC3 in the 2-year
follow-up data. The distribution of variance explained by
each component was similar at baseline and 2 years.
The distribution of LDL peak diameter and its associated LDL subclass phenotypes among the CCI and UC
participants at baseline, 1 and 2 years (Fig. 1) generally
indicates a bimodal distribution consistent with the previous categorization of these phenotypes [24]. In the
CCI group there was a shift in the proportion of LDL
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phenotypes from B to A while no changes were seen in
the UC group (Fig. 1; Additional file 1: Table S6).
Changes in lipoprotein subfractions and CIMT in LDL‑C
and ApoB hypo‑ and hyper‑responders

CCI participants in the quartiles of greatest decrease
and increase in LDL-C and in ApoB from baseline to
2 years were categorized into hypo- and hyper-responder
groups. One-way MANOVA of the lipoprotein subclasses and LDL peak diameter in LDL-C hypo- versus hyper-responders revealed a significant difference
in the overall lipoprotein profile (Pillai’s Trace = 0.66;
F = 5.09, P = 6.0 × 10–6). LDL-C hyper-responders had
significantly greater VLDL medium, VLDL small, IDL I,
IDL II, LDL I, IIa, and IIb compared to hypo-responders
at 2 years (Additional file 1: Table S7). There were no
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significant differences in the lipoprotein profile between
ApoB hypo- and hyper-responders (Pillai’s Trace = 0.37;
F = 1.75, P = 0.37) Additional file 1: Table S8). No differences in mean CIMT at 2 years between the LDL-C
(P = 0.49) and ApoB (P = 0.43) hypo- versus hyperresponders were observed.
Relationships between BMI, CAF, and nutritional ketosis
with lipids and lipoprotein subclasses and phenotypes

Univariate linear regression analyses revealed significant
positive associations of 2 year change in BMI with TG,
large VLDL, LDL IIIa, and LDL IIb, and inverse correlations with HDL-C, IDL II, and HDL2b. Changes in CAF
were positively associated with TG, large VLDL, midzone, LDL IVa, LDL IIIa, LDL IIIb, and LDL IIb, and

Fig. 1 Distribution of LDL phenotype pattern and LDL peak diameters (Å) at baseline, 1 and 2 years. a Continuous care intervention, b usual care
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negatively associated with HDL-C, IDL II, LDL I and
HDL2b (Additional file 1: Table S9). Including both BMI
and CAF in the multiple linear regression model revealed
that only change in BMI was positively associated with
TG and LDL IIIa explaining 39.0% and 32.0% of variance,
respectively, and change in CAF was inversely associated with HDL-C, IDL II, and HDL 2b, explaining 55.0%,
34.0% and 29.0% of the variance, respectively (Additional
file 1: Table S9).
More frequent reporting of nutritional ketosis
(BHB ≥ 0.5 mM) over 2 years was associated with greater
increases in HDL-C, IDL II, and LDL I, and greater
decreases in TG and the mid-zone particle fraction
(Additional file 1: Table S10). Additionally, there was a
significant association between more frequent reporting
of nutritional ketosis with LDL phenotype B to A conversion (Additional file 1: Table S11).

Discussion
Here, we present analyses of changes in CVD risk markers in patients with type 2 diabetes following a 2-year
intervention with a very low carbohydrate diet aimed
at achieving nutritional ketosis. We demonstrated that,
compared with usual care, the very low carbohydrate
diet reduced levels of very small LDL IIIb and increased
concentrations of large LDL and the closely related IDL-2
species [35], with no significant change in total LDL particles and ApoB, a measure of all atherogenic lipoproteins. The results demonstrate a sustained improvement
of the atherogenic lipoprotein phenotype characteristic
of type 2 diabetes that comprises elevated plasma triglyceride and small, dense LDL particles, and reduced HDLcholesterol [11, 12]. Therapies targeting this dyslipidemia
have been reported to mitigate CVD residual risk and
decrease CVD events among patients with diabetes [13,
14, 36].
Notably, the significant increase in LDL-C in the CCI
group was primarily attributed to an increase in larger
cholesterol enriched LDL particles. This is consistent with
the finding that, among LDL subfractions, only larger
LDL I and medium-sized LDL II, but not smaller particles, were significantly greater at 2 years in those in the
upper versus lower quartile of dietary LDL-C response.
The increase in larger LDL is likely due, at least in part, to
high saturated fat intake, which has been shown to preferentially increase levels of these particles, particularly in
the context of reduced carbohydrate intake [15, 16, 37].
Since there is a growing consensus that concentrations of
LDL particles and ApoB are superior to LDL-C as predictors of CVD, particularly when there is discordance
between LDL-C and the particle measures [22, 38], the
present findings, including a lack of increase in total LDL
particles and ApoB, provide reassurance that the increase
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in LDL-C with the dietary intervention does not signify
an increase in CVD risk. This inference aligns with the
observation in the PURE study, where higher dietary saturated fat consumption was associated with higher LDLC, but not with higher all-cause or CVD mortality [39].
Furthermore, this supposition is consistent with lack of
progression of atherosclerosis in our study as assessed
by CIMT. Given the stronger association of small versus
large LDL particles with CVD risk [23–26], it remains
possible that the reduction of very small LDL and other
features of atherogenic dyslipidemia in the CCI group
might lead to improvement in atherosclerosis measures
with a longer-term intervention. A benefit of the dietary
intervention on CVD risk might also be predicted by the
observed reductions in remnant cholesterol [28], as well
as the increases in HDL-C and the HDL protein ApoAI
[40, 41], although recent studies have called into question
whether reduced CVD risk can be reliably inferred by an
increase in HDL-C [42, 43].
Given the evidence for multiple metabolic relationships among the various lipoprotein classes, we turned
to PCA to determine whether the effect of the very low
carbohydrate diet could be defined by one or more independent clusters of inter-related changes in lipoprotein
subfractions. From the baseline data of both the CCI and
UC groups, we identified three independent PCs, all corresponding to PCs previously identified in healthy individuals [26]. The major component in the present study
(PC1) is consistent with PC2 in the earlier report, which
in turn, closely reflects features of the atherogenic lipoprotein phenotype [26]. Notably, this PC has been associated with increased CVD risk [26] and with chronic
kidney disease [44]. Moreover, it has been associated
with a 22% increase in the odds of coronary artery calcification (CAC) in individuals with diabetes and metabolic
syndrome [45] and with CAC in those with reduced kidney function [44]. With dietary intervention in the CCI
group, we found that PC1 shifted from the largest variance contributor at baseline to a secondary variance component. Furthermore, it could then be separated into two
sub-components (PC1a and PC1b). Interestingly, small
LDL IIIa and IIIb were relatively more strongly loaded
onto PC1a, along with triglycerides and medium and
large VLDL (positively) and HDL-C (negatively). In contrast, very small LDL IVa to LDL IVb were more strongly
loaded onto PC1b, along with moderate loading of triglycerides and medium and large VLDL. These distinctions suggest that the very low carbohydrate intervention
may have exposed effects on two independent components of the atherogenic lipoprotein phenotype, involving
small and very small LDL particles, respectively. The dietinduced shift in PC1 from the primary to the secondary contributor to the overall variance is consistent with
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conversion from small LDL phenotype B to phenotype A
in a high proportion of the CCI participants. This finding
is in line with other studies reporting the reversal of phenotype B to A through down-titration of carbohydrate
intake relative to fat intake in healthy individuals [16] and
in those with metabolic syndrome treated with an isocaloric low carbohydrate, high fat diet [17].
PC2 in the present study is consistent with the main
PC (PC1) previously identified in healthy individuals
[26] and is represented by LDL-C as well as large and
medium LDL, IDL and small VLDL. Consistent with the
increase in LDL-C in the CCI group, we showed that the
associated variance in PC2 shifted from a secondary to
the major contributor at 2 years. While the implications
of this shift for CVD remain uncertain, it is notable that
this PC was not found to be associated with CVD risk in
healthy individuals [26] or with CAC in those with diabetes or metabolic syndrome [45].
Finally, the minor PC3, which was associated with
reduced CVD risk in healthy individuals [26] and represents a spectrum of particles ranging from small
HDL2a + 3 and large HDL2b to the smallest LDL species (LDL IVc), was not affected significantly by the dietary intervention. However, there was a trend toward
increased HDL2b, which might have contributed to the
observed increase in HDL-C and ApoAI.
The ion mobility analysis also identified a novel particle
fraction in the size range between LDL and HDL, designated mid-zone, which was significantly reduced in the
CCI group. The loading of this fraction onto PC1b suggests that it may represent a feature of this component
of the atherogenic lipoprotein phenotype. However, it
was also represented in PC3, raising the possibility that it
may be heterogeneous, representing contributions from
both LDL and HDL, and perhaps other particles in this
size range. Further studies will be required to characterize this fraction and determine its metabolic significance
and possible relation to CVD risk.
The findings from this study raise the question as to
the extent to which reduced body weight and central adiposity may have contributed to the lipoprotein changes
induced by the very low carbohydrate diet [15, 46].
Although the study design makes it difficult to disentangle these influences, we found that weight loss, abdominal
fat reduction, and ketosis were differentially associated
with specific lipoprotein particle changes. Both reduction
in BMI and more frequent ketosis were correlated with
improvement in TG, and reduced BMI was associated
with lower levels of small LDLs. On the other hand, ketosis was related to increased large LDL I and conversion
of LDL phenotype B to A, and, along with reduced central adiposity, to increased IDL 2 (closely related to large
LDL [35]) and HDL-C. We speculate that carbohydrate
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restriction in conjunction with weight loss either through
additive or synergistic actions may reduce the availability
of the hepatic triglyceride pool for production of VLDL
precursors of small LDLs [15]. On the other hand, more
frequent ketosis may reflect greater carbohydrate restriction and higher intake of fat, including saturated fat
which, as noted above, preferentially increases level of
larger LDL particles in conjunction with reduced carbohydrate intake [15, 16, 37]. One or both of these dietary
effects may enhance the conversion of LDL phenotype B
to A [16, 47]. Interestingly, a study performed in obese
patients who underwent laparoscopic adjustable gastric
banding failed to show significant changes in LDL levels
and LDL subfractions despite a substantial weight loss of
13.4% at 13 months [48]. Together, these observations,
along with earlier studies [15, 17] suggest that carbohydrate restriction and nutritional ketosis may contribute
significantly to the observed lipoprotein changes independent of changes in adiposity.
A strength of this study is its 2-year duration, the
longest to evaluate lipoprotein changes in response to a
very low carbohydrate diet including nutritional ketosis. While free-living ad libitum food consumption
among participants who self-selected their intervention
enhances the generalizability of the study by mimicking
patient choice in lifestyle intervention for diabetes treatment. Within the CCI group, long term tracking of blood
BHB as a marker of carbohydrate restriction provided
the opportunity to explore the relationship between frequency of reported nutritional ketosis status and shift
from LDL subclass phenotype B to A.
A limitation of this study is the lack of randomization
and lack of tight control over the food consumed by the
CCI and UC groups. In addition, the fact that the study
participants were mostly Caucasian limits the generalizability of the study to other races and ethnic groups.
Finally, the lack of changes in CIMT in the two groups
could be due to insufficient duration of the study or to
variation in image acquisition and interpretation among
the individuals performing this technique. Furthermore, the CIMT analysis did not include carotid plaque
assessment.

Conclusion
In conclusion, these results demonstrate that in patients
with type 2 diabetes, consumption of a very low carbohydrate diet with nutritional ketosis for 2 years was associated with sustained improvement in the atherogenic
lipid and lipoprotein profile that is characteristic of this
condition. This finding was reinforced by the use of an
unbiased principal component analysis that identified
this profile as one of three independent clusters of lipoprotein fractions, another of which accounted for the
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diet-induced increase in LDL-C. While the implications
of these effects for CVD outcomes will require future
long-term studies, both the lack of increase in total LDL
particle number and carotid intima-media thickness
point to the cardiovascular safety of a very low carbohydrate diet in the context of a substantial benefit for management of type 2 diabetes [18].
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